Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Abiraterone: a step forward in the treatment of prostate cancer

Eleni Efstathiou, MD, PhD, from the The University of Texas MD Anderson Cancer Center, Houston, TX, talks to us about the advancement in treating prostate cancer with the androgen biosynthesis inhibitor, abiraterone, at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL. She notes the possibility of limiting the extent of androgen deprivation therapy from the classic 3 years to 1.5 years, as evaluated from the good quality of life data obtained from clinical trials involving the treatment of prostate cancer with abiraterone, and states that this is a big advancement in the treatment of cancer.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.